Moving ear syndrome: The role of botulinum toxin
β Scribed by Clecio Godeiro-Junior; Andre Carvalho Felicio; Evandro Penteado Villar Felix; Gilberto Mastrocola Manzano; Sonia Maria de Azevedo Silva; Vanderci Borges; Henrique Ballalai Ferraz; Orlando G.P. Barsottini
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 68 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
We report a 30βyearβold man with moving ear syndrome caused by focal myoclonic jerks of the right temporal muscle. This focal myoclonus would disappear while the patient was sleeping, swallowing, or speaking. He was treated with botulinum toxin type A with a favorable outcome. Previous reports of this condition and possible therapeutic approaches are discussed. Β© 2007 Movement Disorder Society
π SIMILAR VOLUMES
The role of the physical therapist Muscle & Nerve Supplement 6 1997 Judy Leach, PT In their involvement with children undergoing treatment with botulinum toxin for cerebral palsy (CP), physical therapists are involved in five major areas: Abstract: For the cerebral palsy patient undergoing botulin
## Background: Gustatory sweating is a common complication of parotid surgery. injection of botulinum toxin a has been reported as a safe and effective treatment option for patients with frey's syndrome. ## Patients and methods: A total of 69 patients who had undergone superficial parotidectomy b
Food-borne botulism probably has accompanied mankind since its beginning. However, we have only few historical sources and documents on food poisoning before the 19th century. Some ancient dietary laws and taboos may reflect some knowledge about the life-threatening consumption of poisoned food. One
## Abstract ## Background First bite syndrome is the development of pain in the parotid region after the first bite of each meal and can be seen after surgery of the parapharyngeal space. The purpose of this study is to evaluate the efficacy of intraglandular injection of botulinum toxin type A (B